Houston medical institutions launch $6M kidney research incubator

NIH funding

Houston institutions have landed $6.25 million in NIH funding to launch the HAI-KUH research training program. Photo via UH.

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

From Your Site Articles
Baylor Genetics has paired with Baylor’s department of molecular and human genetics to launch the Medical Genetics Multiomics Laboratory with a goal for the collaboration is to turn research into clinical diagnostics. Photo via Getty Images

This new Houston lab is translating genetics research into clinical diagnostics

DNA innovation

A new lab at Baylor College of Medicine is primed to do groundbreaking work in the field of genetics.

Baylor Genetics has paired with Baylor’s department of molecular and human genetics to launch the Medical Genetics Multiomics Laboratory (MGML). The goal for the collaboration is to turn research into clinical diagnostics.

MGML’s freshly launched first clinical test is Whole Transcriptomic RNA Sequencing (WT RNAseq). The new test builds upon the success of existing tests like whole exome sequencing (WES) and whole genome sequencing (WGS) currently on offer from Baylor Genetics by focusing on additional variants that could be missed by the other tests.

Baylor Genetics is offering WT RNAseq to the Undiagnosed Diseases Network (UDN) and its affiliated institutions. For more than a decade, the NIH-funded UDN has united clinical and research experts from across many fields and institutions to give answers to patients with rare genetic diseases. Since it became one of the first institutions to join the UDN in 2014, Baylor Genetics has been the UDN’s sequencing core, using WES, WGS and RNA sequencing to help diagnose patients. The additional offering of WT RNAseq could improve the diagnostic yield by as much as 17 percent.

“This agreement, and the MGML lab, bring to life our vision of innovation, allowing us to co-develop new tests, evaluate in terms of clinical utility, and offer commercially in either a research or clinical setting,” says Dr. Brendan Lee, professor, chair and Robert and Janice McNair Endowed Chair of Molecular and Human Genetics at Baylor College of Medicine, and scientific advisory and board of directors member at Baylor Genetics. “Baylor Genetics is turning around critical high-volume testing, but the challenge is also maintaining our innovative edge and our position as leaders in discovery and genomic health implementation. This agreement is a realization of the vision when Baylor Genetics was founded 10 years ago.”

The lab’s product offerings will continue to expand as it becomes commercially feasible to do so, and the new tests will be used both commercially and clinically.

Baylor Genetics combines the powers of Baylor College of Medicine, which has the NIH’s best-funded department of molecular and human genetics, and Japanese clinical diagnostic testing company H.U. Group Holdings.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston falls from top 50 in global ranking of 'World's Best Cities'

Rankings & Reports

Houston is no longer one of the top 50 best cities in the world, according to a prestigious annual report by Canada-based real estate and tourism marketing firm Resonance Consultancy.

The newest "World's Best Cities" list dropped Houston from No. 40 last year to No. 58 for 2026.

The experts at Resonance Consultancy annually compare the world's top 100 cities with metropolitan populations of at least 1 million residents or more based on the relative qualities of livability, "lovability," and prosperity. The firm additionally collaborated with AI software company AlphaGeo to determine each city's "exposure to risk, adaptation capacity," and resilience to change.

The No. 1 best city in the world is London, with New York (No. 2), Paris (No. 3), Tokyo (No. 4), and Madrid (No. 5) rounding out the top five in 2026.

Houston at least didn't rank as poorly as it did in 2023, when the city surprisingly plummeted as the 66th best city in the world. In 2022, Houston ranked 42nd on the list.

Despite dropping 18 places, Resonance Consultancy maintains that Houston "keeps defying gravity" and is a "coveted hometown for the best and brightest on earth."

The report cited the Houston metro's ever-growing population, its relatively low median home values ($265,000 in 2024), and its expanding job market as top reasons for why the city shouldn't be overlooked.

"Chevron’s shift of its headquarters from California to Houston, backed by $100 million in renovations, crowns relocations drawn by record 2024 Port Houston throughput of more than four million containers and a projected 71,000 new jobs in 2025," the report said.

The report also draws attention to the city's diversity, spanning from the upcoming grand opening of the long-awaited Ismaili Center, to the transformation of several industrial buildings near Memorial City Mall into a mixed-use development called Greenside.

"West Houston’s Greenside will convert 35,000 square feet of warehouses into a retail, restaurant and community hub around a one-acre park by 2026, while America’s inaugural Ismaili Center remains on schedule for later this year," the report said. "The gathering place for the community and home for programs promoting understanding of Islam and the Ismaili community is another cultural jewel for the country’s most proudly diverse major city."

In Resonance Consultancy's separate list ranking "America's Best Cities," Houston fell out of the top 10 and currently ranks as the 13th best U.S. city.

Elsewhere in Texas, Austin and Dallas also saw major declines in their standings for 2026. Austin plummeted from No. 53 last year to No. 87 for 2026, and Dallas fell from No. 53 to No. 78.

"In this decade of rapid transformation, the world’s cities are confronting challenges head‑on, from climate resilience and aging infrastructure to equitable growth," the report said. "The pandemic, long forgotten but still a sage oracle, exposed foundational weaknesses – from health‑care capacity to housing affordability. Yet, true to their dynamic nature, the leading cities are not merely recovering, but setting the pace, defining new paradigms of innovation, sustainability and everyday livability."

---

This article originally appeared on CultureMap.com.

Waymo self-driving robotaxis will launch in Houston in 2026

Coming Soon

Houston just cleared a major lane to the future. Waymo has announced the official launch of its self-driving robotaxi service in the Bayou City, beginning with employee-only operations this fall ahead of a public launch in early 2026.

The full rollout will include three Texas cities, Houston, Dallas, and San Antonio, along with Miami and Orlando, Florida. Currently, the company operates in the San Francisco Bay Area, Phoenix, and Los Angeles, with service available in Austin and Atlanta through Uber.

Before letting its technology loose on a city, Waymo first tests the routes with human drivers. Once each locale is mapped, the cars can begin driving independently. Unique situations are flagged by specialists, and engineers evaluate performance in virtual replicas of each city.

“Waymo’s quickly entering a number of new cities in the U.S. and around the world, and our approach to every new city is consistent,” explained the announcement. “We compare our driving performance against a proven baseline to validate the performance of the Waymo Driver and identify any unique local characteristics.”

The launch puts Waymo ahead of Tesla. Elon Musk’s Austin-based carmaker has made a lot of hullabaloo about autonomy being the future of the company, but has yet to launch its service on a wide scale.

Waymo started testing San Antonio’s roadways in May as part of a multi-city “road trip,” which also included Houston. The company says its measured approach to launches helps alleviate local concern over safety and other issues.

“The future of transportation is accelerating, and we are driving it forward with a commitment to quality and safety,” Waymo wrote. “Our rigorous process of continuous iteration, validation, and local engagement ensures that we put communities first as we expand.”

---

This article originally appeared on CultureMap.com.

Shipley Donuts launches AI-powered ordering assistant

fresh tech

Popular Houston-born doughnut chain Shipley Donuts has added a first-of-its-kind AI-powered assistant to its online ordering platform.

The new assistant can create personalized order recommendations based on individual or group preferences, according to a news release from the company. Unlike standard chatbox features, the new assistant makes custom recommendations based on multiple customer factors, including budgetary habits, individual flavor preferences and order size.

"We're not just adding AI for the sake of innovation — we're solving real customer pain points by making ordering more intuitive, personalized and efficient," Kerry Leo, Shipley Vice President of Technology, said in the release.

The system also works for larger events, as it can make individual orders and catering recommendations for corporate events and meetings by suggesting quantities and assortments based on group size, event type and budget.

According to Shipley, nearly 1 in 4 guests have completed orders with the new AI technology since it launched on its website.

“The integration of the AI ordering assistant into our refreshed website represents a significant leap forward in how restaurant brands can leverage technology to enhance the customer experience,” Leo added in the release.

View All Listings